Table 4.
Most Common ICD-10-CM Primary Neoplasm-related Codes (C00–D49) Used for the Known Soft-Tissue Sarcoma Cohort (n = 350)
| Code | Number (Percent)a |
|---|---|
| C49, Malignant neoplasm of other connective and soft tissue | 170 (48.6) |
| C78, Secondary malignant neoplasm of lung | 69 (19.7) |
| C79, Secondary malignant neoplasm of bone | 64 (18.3) |
| C48, Malignant neoplasm of retroperitoneum and peritoneum | 23 (6.6) |
| C76, Malignant neoplasm of other and ill-defined sites | 17 (4.9) |
| C34, Malignant neoplasm of bronchus and lung | 10 (2.9) |
| C54, Malignant neoplasm of corpus uteri | 10 (2.9) |
| C80, Malignant neoplasm without specification of site | 9 (2.6) |
| C55, Malignant neoplasm of uterus, part unspecified | 8 (2.3) |
| C22, Malignant neoplasm of liver and intrahepatic bile ducts | 8 (2.3) |
| C50, Malignant neoplasm of breast | 7 (2.0) |
| C41, Malignant neoplasm of bone and articular cartilage of other and unspecified sites | (1.7) |
| C40, Malignant neoplasm of bone and articular cartilage of limbs | 5 (1.4) |
| C61, Malignant neoplasm of prostate | 4 (1.1) |
| C44, Other and unspecified malignant neoplasm of skin | 4 (1.1) |
| C47, Malignant neoplasm of peripheral nerves and autonomic nervous system | (0.9) |
| C53, Malignant neoplasm of cervix uteri | 2 (0.6) |
| C71, Malignant neoplasm of brain | 2 (0.6) |
| C46, Kaposi's sarcoma | 2 (0.6) |
| C96, Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue | (0.6) |
| C64, Malignant neoplasm of kidney, except renal pelvis | 2 (0.6) |
| C62, Malignant neoplasm of testis | 1 (0.3) |
| C57, Malignant neoplasm of other and unspecified female genital organs | 1 (0.3) |
| C25, Malignant neoplasm of pancreas | 1 (0.3) |
| C26, Malignant neoplasm of other and ill-defined digestive organs | 1 (0.3) |
| C00, Malignant neoplasm of lip | 1 (0.3) |
| C69, Malignant neoplasm of eye and adnexa | 1 (0.3) |
| C38, Malignant neoplasm of heart, mediastinum and pleura | 1 (0.3) |
| C67, Malignant neoplasm of bladder | 1 (0.3) |
| C66, Malignant neoplasm of ureter | 1 (0.3) |
| C90, Multiple myeloma and malignant plasma cell neoplasms | 1 (0.3) |
| D49, Neoplasms of unspecified behavior | 9 (2.6) |
| D48, Neoplasm of uncertain behavior and of other and unspecified sites | 6 (1.7) |
| D47, Other neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue | 6 (1.7) |
| D21, Other benign neoplasms of connective and other soft tissue | 2 (0.6) |
| D38, Neoplasms of uncertain behavior of middle ear and respiratory and intrathoracic organs | (0.3) |
| D35, Benign neoplasm of other and unspecified endocrine glands | 1 (0.3) |
| D34, Benign neoplasm of thyroid gland | 1 (0.3) |
| D25, Leiomyoma of uterus | 1 (0.3) |
| D18, Hemangioma and lymphangioma, any site | 1 (0.3) |
| D17, Benign lipomatous neoplasm | 1 (0.3) |
| D12, Benign neoplasm of colon, rectum, anus and anal canal | 1 (0.3) |
| D05, Carcinoma in situ of breast | 1 (0.3) |
a
All C codes were reported within 60 days before or after initiation of known sarcoma therapy; totals may add up to more than 100 percent because of multiple codes used per patient.